Severe infusion reactions to brentuximab vedotin in two patients with Hodgkin lymphoma previously treated with allogeneic stem cell transplantation

Journal of Oncology Pharmacy Practice

Volumn 19, Issue 3, 2013, Pages 279-283

  Baxley, Allison A ^a   Kumm, Debra E ^a   Bishop, Courtney B ^a   Medina, Patrick J ^a   Holter Chakrabarty, Jennifer ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

allogeneic hematopoietic stem cell transplantation; Brentuximab vedotin; Hodgkin lymphoma; infusion reaction

Indexed keywords

BRENTUXIMAB VEDOTIN; BUSULFAN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; HYDROCORTISONE; LORAZEPAM; METHYLPREDNISOLONE; PALONOSETRON; PARACETAMOL; RANITIDINE; SALBUTAMOL;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DRUG EFFECT; DRUG TOLERANCE; ERYTHEMA; FEMALE; HODGKIN DISEASE; HUMAN; INFUSION RELATED REACTION; LARGE CELL LYMPHOMA; MYELOABLATIVE CONDITIONING; POSITRON EMISSION TOMOGRAPHY; PREMEDICATION; PRIORITY JOURNAL; PRURITUS; RECURRENT DISEASE; REED STERNBERG CELL; TACHYCARDIA; THERAPY DELAY; TREATMENT FAILURE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; HODGKIN LYMPHOMA; INFUSION REACTION;

ADULT; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84882243342     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155212464021     Document Type: Article

References (18)

1. American Cancer Society. Cancer Facts and Figures 2011. American Cancer Society 2011; 2012.
2. Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol. 2004 ; 22: 2835-2841
3. Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood. 2008 ; 111: 2977-2983
4. Milpied N, Fielding AK, Pearce RM, et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol. 1996 ; 14: 1291-1296
5. Seattle Genetics Inc. Adcetris [prescribing information]. Bothell, WA, 2011.
6. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007 ; 12: 601-609
7. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999 ; 17: 791-795
8. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003 ; 63: 803-843
9. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002 ; 29: 2-9
10. Younes A. CD30-targeted antibody therapy. Curr Opin Oncol. 2011 ; 23: 587-593
11. Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res. 2011 ; 17: 6428-6436
12. DeNardo GL, Bradt BM, Mirick GR, et al. Human antiglobulin response to foreign antibodies: therapeutic benefit?. Cancer Immunol, Immunother. 2003 ; 52: 309-316
13. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol. 1994 ; 15: 42-52
14. Mirick GR, Bradt BM, Denardo SJ, et al. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging. 2004 ; 48: 251-257
15. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990 ; 75: 1011-1016
16. Schots R, Kaufman L, Van Riet I, et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia. 2003 ; 17: 1150-1156
17. Hubel K, Cremer B, Heuser E, et al. A prospective study of serum soluble CD30 in allogeneic hematopoietic stem cell transplantation. Transpl Immunol. 2010 ; 23: 215-219
18. Gruss HJ, Pinto A, Duyster J, et al. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today. 1997 ; 18: 156-163